OM:CRNO BBiotechs
Cereno Scientific (OM:CRNO B) Stock Trails Revenue Spike As Cash Runway Shrinks
Cereno Scientific stock has been grinding lower for months, and today investors had to decide whether another biotech loss story deserves a premium P/S of 20.6x. The headline is blunt. Revenue for Q2 2026 landed at SEK52.6 million, yet the company still reported a net loss of SEK30.5 million and remains unprofitable over the past year.
For a drug developer with less than one year of cash runway and forecasts pointing to no revenue next year, this earnings print is a sentiment test. The...